Zion Therapeutics, LLC Report issue

For profit Phase 3
Founded: St George UT United States (2018)
Status: No NME R&D (2018)

Organization Overview

First Clinical Trial
2018
NCT03244072
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Jason Ahee, M.D. | Zion Therapeutics, LLC

Active Ingredients

Drugs in Phase 3 Trials (1)

moxifloxacin (avelox) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Capsule Opacification (Phase 3)

Cataract (Phase 3)

Endophthalmitis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1